The global AL amyloidosis therapeutics market is anticipated to witness substantial growth in the coming years, with projections indicating a value of US$ 2.25 billion by 2023 and a further increase to US$ 4.56 billion by 2033 to rise at a 7.3% CAGR until 2033, according to a report by Future Market Insights.
AL amyloidosis is a rare disease characterized by abnormal protein accumulation in organs and tissues, often leading to organ damage and deterioration. Symptoms include weight loss, weakness, fatigue, difficulty breathing, joint pain, and skin manifestations such as redness and spider veins. The rising incidence rates of AL amyloidosis, particularly among the aging population, are driving the demand for therapeutic interventions.
Get your Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-16805
The increase in diagnosis rates, with approximately 4,000 cases reported annually in the United States alone, predominantly among individuals aged 50 to 65, underscores the need for effective treatments. Moreover, the expansion of innovative therapeutic options and advancements in medical technologies contribute to the growth of the market.
Governments worldwide are actively funding research and development initiatives for AL amyloidosis treatments, facilitating the availability of advanced diagnostics and medical therapies. This support is expected to bolster market growth, particularly in developed countries with robust healthcare infrastructure.
Chemotherapy remains a cornerstone of AL amyloidosis treatment, experiencing rapid growth due to its efficacy and patient preference. Additionally, targeted therapies such as anti-angiogenesis treatment, monoclonal antibodies, and proteasome inhibitors are poised to witness accelerated adoption in the coming years, opening new avenues for market expansion.
“The global AL amyloidosis therapeutics market is poised for significant growth, driven by factors such as increasing diagnosis rates, advancements in treatment options, and supportive government initiatives,” commented a spokesperson from Future Market Insights.
As the demand for effective AL amyloidosis treatments continues to rise, stakeholders across the healthcare sector are focusing on innovation and collaboration to address unmet medical needs and improve patient outcomes.
Key Takeaways from the Market Study:
- The market for treatments for AL amyloidosis expanded at a CAGR of 5.1% from 2018 to 2022.
- More than US$ 2.1 billion is presently spent on treating AL amyloidosis worldwide.
- Chemotherapy is predicted to command the market in 2023 with a 53% revenue share.
- The hospital pharmacy sector by distribution channel will hold the second-largest segment during the anticipated period, with a 25% worldwide market share in 2023.
- From 2023 to 2033, the North American region is expected to expand at a constant CAGR of 7.9%.
- From 2023 to 2033, the Asia Pacific AL amyloidosis therapies market is anticipated to expand at a stable CAGR of 7.6%.
“Due to factors including rising incidence as well as the anticipated introduction of innovative therapeutics throughout the projected period, the market for AL amyloidosis therapeutics is predicted to rise favorably.” comments a Future Market Insights analyst.
Request Methodology Now: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16805
Competitive Landscape:
Some of the top players in the global intraocular lymphoma disease market are:
- Janssen Pharmaceutical
- Prothena
- Alexion Pharmaceuticals
- Oncopeptides AB
- Bristol-Myers Squibb
- GlaxoSmithKline Pharmaceuticals Ltd
- Celgene Corp
- Eidos Therapeutics, Inc.
- Corino Therapeutics, Inc.
- Spectrum Pharmaceuticals, Inc.
- Pfizer
Some of the recent developments in this domain are:
- The U.S. Food and Drug Administration (FDA) approved Sorrento Therapeutics, Inc.’s experimental new drug application for STI-6129, a CD38-targeting monoclonal antibody combination, in 2020. Sorrento Therapeutics is currently working on a number of technological platforms, along with a CD38-specific antibody found in its completely human G-MABTM antibody library, its own pharmacological payload Duostatin 5, as well as its site-specific C-LOCK coupling technology. These platforms are all used by STI-6129.
Key Segments Covered in the AL amyloidosis therapeutics market Report:
By Treatment:
- Chemotherapy
- Supportive Care
- Surgery
- Stem Cell Transplant
- Targeted Therapy
By Drugs:
- Transthyretin Transport Inhibitor
- Immunomodulatory Drugs
- Monoclonal Antibodies
- Proteasome Inhibitors
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Direct Purchase of this Report: https://www.futuremarketinsights.com/checkout/16805
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
